Posts by Mourabit Halima

The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) took place from March 12–15, 2025, in Vienna, Austria. On the third day (March 14), Professor Cicero Urban, Bioethics and Scientific…

The 19th St.Gallen  Breast Cancer Conference (SGBCC 2025) was held from March 12–15, 2025, in the music capital of Vienna, Austria. The "Voice of China" session at this conference provided…

Published on February 10, 2025, in Cancer Cell, this international effort led by Carsten Denkert and colleagues investigates the dynamics of therapy-induced molecular heterogeneity in high-risk HR+/HER2− breast cancer, using…

In the treatment of low rectal cancer, the “watch and wait” strategy has sparked a compelling debate between organ preservation and radical resection. With the advancement of neoadjuvant therapies, some patients achieve clinical complete response (cCR) following chemoradiotherapy, opening the door to non-operative management and the possibility of avoiding a permanent stoma. However, concerns over local regrowth, subjective response assessment, and the psychological burden on patients continue to challenge the broader application of this approach.

From February 28 to March 1, 2025, the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee was held in Beijing. This year’s meeting focused on the standardization, precision, and personalization of colorectal cancer diagnosis and treatment, drawing top experts from China and around the world to explore the latest advances in the field.

At the recently concluded 97th Annual Meeting of the Japanese Gastric Cancer Association (JGCA 2025) in Nagoya, the surgical oncology team from The Affiliated Hospital of Qingdao University , led…

On March 2025, The Lancet Oncology published results from the UCBG 3-06 START phase 2 trial, comparing darolutamide and capecitabine in patients with triple-negative, androgen receptor-positive (AR+) advanced breast cancer.Although…

In a landmark phase 3 trial published in Nature Medicine, Prof. Sherene Loi and colleagues investigated whether immunotherapy can shift the treatment paradigm in high-risk early ER+/HER2− breast cancer.The study…

As lung cancer diagnosis and treatment enter an era of precision and personalization, Chinese researchers are playing an increasingly pivotal role on the international stage through innovation and collaboration. In this special edition of the Mok Talk interview series, hosted by the talented Professor Yang Xia of The Second Affiliated Hospital of Zhejiang University School of Medicine, we are honored to present a conversation with world-renowned lung cancer expert Professor Tony Mok from The Chinese University of Hong Kong. Joining him are prominent early-career scholars such as Professor Wenhua Liang (The First Affiliated Hospital of Guangzhou Medical University) and Professor Yongchang Zhang (Hunan Cancer Hospital). Together, they discuss academic growth, clinical trial design, and the global impact of Chinese innovations—offering a meaningful intergenerational exchange of ideas.